Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.
about
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitorsClinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyTransgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicityAnti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitroSaquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administrationThe effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individualsThe effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects.Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.Reliability and validity of daily self-monitoring by smartphone application for health-related quality-of-life, antiretroviral adherence, substance use, and sexual behaviors among people living with HIV.Significant interactions with new antiretrovirals and psychotropic drugs.Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg.Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposureClinical management of selected oral fungal and viral infections during HIV-disease.Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.Correlates of safer sex communication among college students.Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death.Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 micePharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients.Metabolomic screening and identification of the bioactivation pathways of ritonavirAntiretroviral therapy for patients with HIV diseaseEffect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in manEffect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.Group interventions for patients with cancer and HIV disease: part IV. Clinical and policy recommendations.Drug interactions in the management of HIV infection.Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.Safety of pharmacoenhancers for HIV therapy.Darunavir/cobicistat once daily for the treatment of HIV.Protease inhibitors as antiviral agents.Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture.Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment.Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assayPharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals.Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers.Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.A mechanistic theory to explain the efficacy of antiretroviral therapy.
P2860
Q24554340-AF9AC60B-BA60-442D-9FED-10523632FB71Q26771182-8851C5C8-CFF3-4BB2-9253-ED304DEFFFF7Q28087473-15999DF2-1190-4B80-8F80-FE03818147E1Q28344611-C56797E3-765D-4EE1-ABDE-6E7C76133A22Q28354163-BB82FD74-028E-422D-BA93-DD74A7996429Q28367578-8BB65A8B-52C8-4961-A2EB-F88F1B4C1A19Q30692710-F2D136D9-81C4-4EA4-928A-C45776AB0382Q31106166-F9C91CDF-AF4C-4B39-90BE-98FE0E9D95B6Q33148910-57BF3F75-FA33-4C9B-A134-FBF4EF4F1CBEQ33441876-66D1CDCA-C6D8-4563-911F-CC5BC5863235Q33637697-B6705A1B-1AF5-4A32-92EB-21D8F6A5BA41Q33735372-A87F2A31-984E-4022-B058-6B42D4F1752AQ33902161-7A8D5B6A-1403-4659-BD64-617CA35B671DQ33945706-4AE5C4DE-2F16-4F5E-AEA6-13E72FE834C9Q33983571-6116166F-4F5F-4E4E-A0A2-59187191029BQ34050006-DA5D3959-D09F-49F0-8135-74D830791B49Q34113462-EE0AF0BE-C212-4BEE-98A6-8C763C8D534AQ34340138-A590C351-5CAE-42E9-BBD1-1569EA03CE59Q34349192-FBB3E081-E397-4ECD-9BFD-D921F596A824Q34936881-1B0BF06C-D840-4646-A459-04EEB11F7EBCQ35626853-6736BA54-6C91-4D9E-A7E5-70B2C30420DDQ35802185-6AE47F77-0A15-4AFA-B67E-B45CBEFFB1B6Q35802558-6F8024F1-B5E0-406B-BAE0-30E95D0798D6Q35803002-AD6E7CCB-1FCA-4F1E-85FA-337567185FF4Q35827661-BE4C8A7A-338C-44DC-8397-1AB37C82A487Q35896912-6F4E8DA3-C335-44D7-9523-140671B320FAQ36066083-934641CE-FA04-4354-8378-605CBD529FF2Q36132255-A0CB2A0A-2DFE-4915-A555-20EDF6F2EDADQ36376533-0D66F9CE-3FBD-44B3-9C64-814650304460Q36870827-D7F142CE-7388-41CC-8F1B-F0579460C025Q38057371-6DF91297-22D4-49C1-803E-152251248D22Q38472696-7306CAA7-0D13-4AEC-B1D1-552F27837B86Q39468942-EDF804FF-A30D-47F2-B03C-E67F6F3601AAQ39472141-24B5D793-C6F9-4DD0-9B56-794B3F0B4BD3Q39581119-B2987B57-252E-407F-9455-05B0FBD9E315Q40417013-8B066D84-CE4D-4499-9068-F3884506B960Q41593390-B111E56B-BB9E-4E4F-BA6A-97E61E6D6456Q42618223-C9F1A5F2-F253-47C0-BB62-67C7682707B0Q42931493-DD49F715-212C-461B-930D-8B6FF4219FB8Q43721565-6A3F22CE-83CE-4CF0-BF10-4D172BC47DC6
P2860
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.
description
1997 nî lūn-bûn
@nan
1997 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մարտին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Saquinavir pharmacokinetics al ...... avir in HIV-infected patients.
@ast
Saquinavir pharmacokinetics al ...... avir in HIV-infected patients.
@en
Saquinavir pharmacokinetics al ...... avir in HIV-infected patients.
@nl
type
label
Saquinavir pharmacokinetics al ...... avir in HIV-infected patients.
@ast
Saquinavir pharmacokinetics al ...... avir in HIV-infected patients.
@en
Saquinavir pharmacokinetics al ...... avir in HIV-infected patients.
@nl
prefLabel
Saquinavir pharmacokinetics al ...... avir in HIV-infected patients.
@ast
Saquinavir pharmacokinetics al ...... avir in HIV-infected patients.
@en
Saquinavir pharmacokinetics al ...... avir in HIV-infected patients.
@nl
P2093
P1433
P1476
Saquinavir pharmacokinetics al ...... avir in HIV-infected patients.
@en
P2093
Breckenridge AM
Gibbons SE
P304
P356
10.1097/00002030-199704000-00001
P407
P577
1997-03-01T00:00:00Z